Akamine, T., Nishimura, Y., Ito, K., Uji, Y., Yamamoto, T. Effects of haloperidol on K+ currents in acutely isolated rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 43, 1257–1261 (2002).
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., McGeer, P.L., O'Banion, M.K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van-Muiswinkel, F.L, Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., Wyss-Coray, T. Inflammation and Alzheimer’s disease. Neurobiol.
Aging. 21, 383–421 (2000).
Anthony, D.C., Miller, K.M., Fearn, S., Townsend, M.J., Opdenakker, G., Wells, G.M., Clements, J.M., Chandler, S., Gearing, A.J., Perry, V.H.
Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J. Neuroimmunol.
87, 62–72 (1998).
Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.C., Moskowitz, M.A., Fini, M.E., Lo, E.H. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724–7732 (2001).
Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer. 2, 420-430 (2002).
Avent, K.M., Riker, R.R., Fraser, G.L., Van der Schyf, C.J., Usuki, E., Pond, S.M. Metabolism of haloperidol to pyridinium species in
patients receiving high doses intravenously: is HPTP an intermediate?
Life Sci. 61, 2383-2390 (1997).
Baeuerle, P.A., Baichwal, V.R. NF-κB as a frequent target for
immunosuppressive and anti-inflammatory molecules. Adv. Immunol.
65, 111–137 (1997).
Baldwin, A.S. Jr., The NF-kappa B and I kappa B proteins: new
discoveries and insights. Annu. Rev. Immunol. 14, 649-683 (1996).
Barnes, P.J., Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066–1071 (1997).
Bartholomé, E.J., Van Aelst, I., Koyen, E., Kiss, R., Willems, F., Goldman, M., Opdenakker, G. Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. J.
Interferon Cytokine Res. 21, 495–501 (2001).
Baud, V., Karin, M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11, 372-377 (2001).
Bauvois, B., Dumont, J., Mathiot, C., Kolb, J.P. Production of MMP 9 in early stage B-CLL: supression by interferons. Leukemia 16, 791–798 (2002).
Beg, A.A., Finco, T.S., Nantermet, P.V., Baldwin, A.S. Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol. Cell Biol. 13, 3301–3310 (1993).
Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S., Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376, 167-170 (1995).
Beutler, B. Tlr4: central component of the sole mammalian LPS sensor.
Curr. Opin. Immunol. 12, 20–26 (2000).
Bhakar, A.L., Tannis, L.L., Zeindler, C., Russo, M.P., Jobin, C., Park, D.S., MacPherson, S., Barker, P.A. Constitutive nuclear factor-kappa B activity is required for central neuron survival. J. Neurosci. 22, 8466-8475 (2002).
Bjerre, A., Brusletto, B., Ovstebo, R., Joo, G.B., Kierulf, P., Brandtzaeg, P. Identification of meningococcal LPS as a major monocyte activator in IL-10 depleted shock plasmas and CSF by blocking the
CD14-TLR4 receptor complex. J. Endotoxin Res. 9, 155–163 (2003).
Blondeau, N., Widmann, C., Lazdunski, M., Heurteaux, C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J.
Neurosci. 21, 4668-4677 (2001).
Bond, M., Fabunmi, R.P., Baker, A.H., Newby, A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and
inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 435, 29-34 (1998).
Brandtzaeg, P., Bjerre, A., Ovstebo, R., Brusletto, B., Joo, G.B., Kierulf, P. Neisseria meningitidis lipopolysaccharides in human pathology.
Journal of. Endotoxin Res. 7, 401–420 (2001).
Brandtzaeg, P., Ovstebo, R., Kierulf, P. Compartmentalization of
lipopolysaccharide production correlates with clinical presentation in meningococcal disease. J. Infect. Dis. 166, 650–652 (1992).
Brenner, D.A., O'Hara, M., Angel, P., Chojkier, M., Karin, M. Prolonged activation of jun and collagenase genes by tumour necrosis
factor-alpha. Nature 337, 661-663 (1989).
Brew, K., Dinakarpandian, D., Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim.
Biophys. Acta. 7, 1- 2 (2000).
Brown, K., Park, S., Kanno, T., Franzoso, G., Siebenlist, U. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc. Natl. Acad. Sci. U.S.A. 90, 2532- 2536 (1993).
Brown, P.D. Ongoing trials with matrix metalloproteinase inhibitors.
Expert. Opin. Investig. Drugs. 9, 2167–2177 (2000).
Carmeliet, P., Moons, L., Lijnen, R., Baes, M., Lemaitre, V., Tipping, P., Drew, A., Eeckhout, Y., Shapiro, S., Lupu, F., Collen, D.
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17, 439- 444 (1997).
Carter, A., Pietrzkowski, Z., Gewirtz, A.M. Role of vascular endothelial growth factor (VEGF), placenta derived growth factor (PlGF)/Flt-1 andFlk-1/KDR receptor axes in human adult and fetal hematopoiesis.
Br. J. Haematol. 103, 969–979 (1998).
Carter, B.D., Kaltschmidt, C., Kaltschmidt, B., Offenhauser, N., Bohm- Matthaei, R., Baeuerle, P.A. and Barde, Y.A. Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. Science 272, 542-545 (1996).
Castagnoli, N. Jr, Castagnoli K.P., Van der Schyf C.J., Usuki E., Igarashi K., Steyn S.J., Riker R.R. Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins. Pol. J. Pharmacol. 51, 31-38 (1999).
Chen, H., Zhang, S.M., Hernan, M.A., Schwarzschild, M.A., Willett, W.C., Colditz, G.A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059–1064 (2003).
Chinnaiyan, A.M., Tepper, C.G., Seldin, M.F., O’Rourke, K., Kischkel, F.C., Hellbardt, S., Krammer, P.H., Peter, M.E., Dixit, V.M.
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem. 271, 4961–4965 (1996).
Chong, Y.H., Sung, J.H., Shin, S.A., Chung, J.H., Suh, Y.H. Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer’s amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. J. Biol.
Chem. 276, 23511–23517 (2001).
Cohen, J. The immunopathogenesis of sepsis. Nature 420, 885–891 (2002).
Colton, C.A., Keri, J.E., Chen, W.T., Monsky, W.L. Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J. Neurosci. Res. 35, 297-304 (1993).
Combs, C.K., Johnson, D.E., Cannady, S.B., Lehman, T.M., Landreth, G.E. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of b-amyloid and prion proteins. J. Neurosci. 19, 928–939 (1999).
Coussens, L.M., Fingleton, B., Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002).
Curran, S., Murray, G.I. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur. J. Cancer. 36, 1621–1630 (2000).
Czuczwar, S.J., Patsalos, P.N. The new generation of GABA enhancers.
CNS Drugs. 15, 339- 350 (2001).
Davis, R.J. MAPKs: new JNK expands the group. Trends Biochem. Sci.
19, 470-473 (1994).
de Bont, E.S., Rosati, S., Jacobs, S., Kamps, W.A., Vellenga, E. Increased bone marrow vascularization in patients with acute myeloid
leukaemia: a possible role for vascular endothelial growth factor. Br.
J. Haematol. 113, 296–304 (2001).
Deckers, C.L., Czuczwar, S.J., Hekster, Y.A., Keyser, A., Kubova, H., Meinardi, H., Patsalos, P. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 41, 1364–1374 (2000).
DeCoster, M.A., Klette, K.L., Knight, E.S., Tortella, F.C. Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res. 671, 45-53 (1995).
Devy, L., Hollender, P., Munaut, C., Colige, A., Garnotel, R., Foidart, J.M, Noel, A., Jeannesson, P. Matrix and serine protease expression during leukemic cell differentiation induced by aclacinomycin and
all-trans-retinoic acid. Biochem. Pharmacol. 63, 179–189 (2002).
Di Raimondo, F., Palumbo, G.A., Azzaro, M.P., Giustolisi, R.
Angiogenesis in acute myeloid leukemia. Blood 96, 3656 (2000).
DiDonato, J.A., Hayakawa, M., Rothwarf, D.M., Zandi, E., Karin, M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388, 548-554 (1997).
Egeblad, M., Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161–174 (2002).
Egeblad, M., Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 3, 3161-3174 (2002).
Ehrlich, L.C., Hu, S., Sheng, W.S., Sutton, R.L., Rockswold, G.L., Peterson, P.K., Chao, C.C. Cytokine regulation of human microglial cell IL-8 production. J. Immunol. 160, 1944-1948 (1998).
English, J.M., Cobb, M.H. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol. Sci. 23, 40-45 (2002).
Eyles, D.W., McGrath, J.J., Pond, S.M. Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacol (Berl).
125, 214-219 (1996).
Firestein, G.S., Manning, A.M. Wignal transduction and transcription factors in rheumatic disease. Arthritis Rheum. 42, 609-621 (1999).
Fischer, C., Page, S., Weber, M., Eisele, T., Neumeier, D., Brand, K.
Differential effects of lipopolysaccharide and tumor necrosis factor on monocytic IkappaB kinase signalsome activation and IkappaB
proteolysis. J. Biol. Chem. 274, 24625-24632 (1999).
Fridmacher, V., Kaltschmidt, B., Goudeau, B., Ndiaye, D., Rossi, F.M., Pfeiffer, J., Kaltschmidt, C., Israel, A., Memet, S. Forebrainspecific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection. J. Neurosci. 23, 9403-9408 (2003).
Fujihara, M., Muroi, M., Tanamoto, K., Suzuki, T., Azuma, H., Ikeda, H.
Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol. Ther.
100, 171-194 (2003).
Galizzi, J.P., Fosset, M., Romey, G., Laduron, P., Lazdunski, M.
Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors. Proc. Natl. Acad. Sci. U.S.A. 83, 7513–7517 (1986).
Gamble, J.R., Harlan, J.M., Klebamoff, S.J., Vadas, M.A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl. Acad. Sci. U.S.A. 82, 8667- 8671 (1985).
Gaur, U., Aggarwal, B.B. Regulation of proliferation, survival and
apoptosis by members of the TNF superfamily. Biochem. Pharmacol.
66, 1403-1408 (2003).
Gessner, G., Heinemann, S.H. Inhibition of hEAG1 and hERG1
potassium channels by clofilium and its tertiary analogue LY97241.
Br. J. Pharmacol. 138, 161–171 (2003).
Ghosh, S., Baltimore, D. Activation in vitro of NF-kappa B by
phosphorylation of its inhibitor I kappa B. Nature 344, 678- 682
(1990).
Ghosh, S., Karin, M. Missing pieces in the NF-kappa B puzzle. Cell 109, S81- S96 (2002).
Ghosh, S., May, M.J., Kopp, E.B. NF-kappa B and Rel proteins:
evolutionarily conserved mediators of immune responses. Annu. Rev.
Immunol. 16, 225-260 (1998).
Gijbels, K., Masure, S., Carton, H., Opdenakker, G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41, 29–34 (1992).
Gijbels, K., Proost, P., Masure, S., Carton, H., Billiau, A., Opdenakker, G.
Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J.
Neurosci. Res. 36, 432–440 (1993).
Gijbels, K., Proost, P., Masure, S., Carton, H., Billiau, A., Opdenakker, G.
Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J.
Neurosci. Res. 36: 432–440 (1993).
Giulian, D., Vaca, K., Noonan, C.A. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 250, 1593–1596 (1990).
Glimaker, M., Kragsbjerg, P., Forsgren, M., Olcen, P. Tumor necrosis factor-alpha (TNF alpha) in cerebrospinal fluid from patients with meningitis of different etiologies: high levels of TNF alpha indicate bacterial meningitis. J. Infect. Dis. 167, 882-889 (1993).
Goldberg, G.I., Strongin, A., Collier, I.E., Genrich, L.T., Marmer, B.L.
Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem. 267, 4583–4591 (1992).
Gottschall, P.E., Deb, S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons.
Neuroimmunomodulation. 3, 69-75 (1996).
Gross, J., Lapiere C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. U.S.A. 48, 1014-1022 (1962).
Guerrini, L., Blasi, F., Denis-Donini, S. Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Proc. Natl.
Acad. Sci. U.S.A. 92, 9077-9081 (1995).
Guha, M., Mackman, N. LPS induction of gene expression in human monocytes. Cell Signal 13, 85- 94 (2001).
Gum, R., Lengyel, M., Juarez, J., Chen, J.H., Sato, H., Seiki, M., Boyd, D.
Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J. Biol. Chem. 271, 10672- 10680 (1996).
Hamanoue, M., Middleton, G., Wyatt, S., Jaffray, E., Hay, R.T., Davies, A.M. p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol.
Cell Neurosci. 14, 28-40 (1999).
Hambleton, J., Weinstein, S.L., Lem, L., DeFranco, A.L. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc. Natl. Acad. Sci. U.S.A. 93, 2774-2778 (1996).
Han, J., Lee, J.D., Bibbs, L., Ulevitch, R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811 (1994).
Hanemaaijer, R., Verheijen, J.H., Maguire, T.M., Visser, H., Toet, K., McDermott, E., O'Higgins, N., Duffy, M.J. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int.
J. Cancer 86, 204–207 (2000).
Hardiman, G., Rock, F.L., Balasubramanian, S., Kastelein, R.A., Bazan, J.F. Molecular characterization and modular analysis of human MyD88. Oncogene 13, 2467–2475 (1996).
Harkness, K.A., Adamson, P., Sussman, J.D., Davies-Jones, G.A., Greenwood, J., Woodroofe, M.N. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium.
Brain 123, 698-709 (2000).
Hawiger, J., Veach, R.A., Liu, X.Y., Timmons, S., Ballard, D.W. IkappaB kinase complex is an intracellular target for endotoxic
lipopolysaccharide in human monocytic cells. Blood 94, 1711-1716 (1999).
Herdegen, T., Waetzig, V. AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration.
Oncogene 20, 2424–2437 (2001).
Hidalgo, M., Eckhardt, S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93, 178–193 (2001).
Hoekstra, R., Eskens, F.A., Verweij, J. Matrix metalloproteinase
inhibitors: current developments and future perspectives. Oncologist 6, 415–427 (2001).
Hohmann, H.P., Remy, R., Brockhaus, M., van Loon, A.P. Two different cell types have different major receptors for human tumor necrosis factor (TNF-α). J. Biol. Chem. 264, 14927- 14934 (1989).
Hrabec, E., Strek, M., Greger, J., Nowak, D., Suwalski, M., Hrabec, Z.
Matrix metalloproteinases in lung cancer. Curr. Pneumol. 2, 57–561 (1998).
Hsu, H., Shu, H.B., Pan, M.G., Goeddel, D.V. TRADD-TRAF2 and
TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84, 299–308 (1996).
Hsu, H., Xiong, J., Goeddel, D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81, 495–504 (1995).
Hu, X. Proteolytic signaling by TNFalpha: caspase activation and IkappaB degradation. Cytokine 21, 286-294 (2003).
Hu, X., Tang, M., Fisher, A.B., Olashaw, N., Zuckerman, K.S. Tumor necrosis factor (TNF) α-induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-kappa B activation. J. Immunol. 163,
3106–3115 (1999).
Humphries, H.E., Triantafilou, M., Makepeace, B.L., Heckels, J.E., Triantafilou, K., Christodoulides, M. Activation of human meningeal cells is modulated by lipopolysaccharide (LPS) and non-LPS
components of Neisseria meningitidis and is independent of Toll-like receptor (TLR)4 and TLR2 signalling. Cell Microbiol. 7, 415-430 (2005).
Ichikawa, J., Meltzer, H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin.
Neurosci. 249, Suppl 4: 90- 98 (1999).
Imler, J.L., Hoffmann, J.A. Toll and Toll-like proteins: an ancient family of receptors signaling infection. Rev. Immunogenet. 2, 294–304 (2000).
Ismair, M.G., Ries, C., Lottspeich, F., Zang, C., Kolb, H.J., Petrides, P.E.
Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-alpha (TNF-alpha) in NB4 leukemic cells: specific involvement of TNF receptor type 1.
Leukemia 12, 1136-1143 (1998).
Itoh, T., Tanioka, M. Yoshida, H., Yoshioka, T., Nishimoto, H., Itohara, S.
Reduced angiogenesis and tumor progression in gelatinase A deficient mice. Cancer Res. 58, 1048–1051 (1998).
Ivanov, V., Ronai, Z. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappa B activity and Fas expression. Oncogene 19, 3003–3012 (2000).
Janowska-Wieczorek, A., Majka, M., Marquez-Curtis, L., Wertheim, J.A., Turner, A.R., Ratajczak, M.Z. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 16, 1160-1166 (2002).
Janowska-Wieczorek, A., Marquez, L.A., Dobrowsky, A., Ratajczak, J., Cabuhat, M.L. Differential MMP and TIMP production by human marrow and peripheral blood CD34+ cell in response to chemokines.
Exp. Hematol. 28, 1274–1285 (2000).
Janowska-Wieczorek, A., Marquez, L.A., Matsuzaki, A., Hashmi, H.R., Larratt, L.M., Boshkov, L.M., Turner, A.R., Zhang, M.C., Edwards, D.R., Kossakowska, A.E. Expression of matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br. J. Haematol. 105, 402–411 (1999a).
Janowska-Wieczorek, A., Marquez, L.A., Nabholtz, J.M., Cabuhat, M.L., Montano, J., Chang, H., Rozmus, J., Russell, J.A., Edwards, D.R., Turner, A.R. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. Blood 93, 3379–3390 (1999b).
Janssen, P.A. The pharmacology of haloperidol. Int. J. Neuropsychiatry 3, Suppl 1, 10- 18 (1967).
Jiang, Q.Q., Akashi, S., Miyake, K., Petty, H.R. Cutting edge:
lipopolysaccharide induces physical proximity between CD14 and Toll-like receptor 4 (TLR4) prior to nuclear translocation of
NF-kappa B. J. Immunol. 165, 3541–3544 (2000).
Jiang, Y., Woronicz, J.D., Liu, W., Goeddel, D.V. Prevention of
constitutive TNF receptor 1 signaling by silencer of death domains.
Science 283, 543–546 (1999).
Kaltschmidt, C., Kaltschmidt, B. and Baeuerle, P.A. Stimulation of
ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons. Proc. Natl. Acad. Sci. U.S.A. 92, 9618-9622 (1995).
Kapur, S., Remington, G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52, 503–517 (2001).
Karin, M. How NF-kappa B is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18, 6867-6874 (1999).
Klegeris, A., Bissonnette, C.J., McGeer, P.L. Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system. Neurobiol. Aging 26, 673-682 (2005).
Klein, G., Vellenga, E., Fraaije, M.W., Kamps, W.A., de Bont, E.S. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol. 50, 87–100 (2004).
Kobayashi, T., Ikeda, K., Kumanishi, T. Inhibition by various
antipsychotic drugs of the G-protein-activated inwardly rectifying K+ (GIRK) channels expressed in xenopus oocytes. Br. J. Pharmacol.
129, 1716–1722 (2000).
Koistinaho, M and Koistinaho, J. Role of p38 and p44/42
mitogen-activated protein kinases in microglia. Glia. 40, 175-183 (2002).
Kudo, S., Ishizaki, T. Pharmacokinetics of haloperidol: an update. Clin.
Pharmacokinet. 37, 435- 456 (1999).
Kuittinen, O., Savolainen, E.R., Koistinen, P., Mottonen, M.,
Turpeenniemi-Hujanen, T. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk. Res. 25, 125–131 (2001).
Lai, W.C., Zhou, M., Shankavaram, U., Peng, G., Wahl, L.M. Differential regulation of lipopolysaccharide-induced monocyte matrix
metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J.
Immunol. 170, 6244- 6249 (2003).
Lambert, E., Dasse, E., Haye, B., Petitfrere, E. TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol. 49, 187-198 (2004).
Lamoreaux, W.J., Fitzgerald, M.E., Reiner, A., Hasty, K.A., Charles, S.T.
Vascular endothelial growth factor increases release of gelatinase A andd ecreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc. Res. 55, 29–42 (1998).
Leber, T.M., Balkwill, F.R. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br. J.
Cancer 78, 724-732 (1998).
Lee, F.S., Hagler, J., Chen, Z.J., Maniatis, T. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88, 213-222 (1997).
Lee, K.S., Rha, S.Y., Kim, S.J., Kim, J.H., Roh, J.K., Kim, B.S., Chung, H.C. Sequential activation and production of matrix
metalloproteinase-2 during breast cancer progression. Clin. Exp.
Metastas. 14, 512–519 (1996).
Leppert, D., Hauser, S.L., Kishiyama, J.L., An, S., Zeng, L., Goetzl, E.J.
Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J. 9, 1473-1481 (1995).
Li, L., Cousart, S., Hu, J., McCall, C.E. Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells. J.
Biol. Chem. 275, 23340-23345 (2000).
Lin, L.I., Lin, D.T., Chang, C.J., Lee, C.Y., Tang, J.L., Tien, H.F. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br. J. Haematol. 117, 835–841 (2002).
Ling, L., Cao, Z., Goeddel, D.V. NF-kappa B-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc. Natl. Acad. Sci.
U.S.A. 95, 3792-3797 (1998).
Liu, B., Hong, J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for
therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 1–7 (2003).
Lockhart, B.P., Soulard, P., Benicourt, C., Privat, A., Junien, J.L. Distinct neuroprotective profiles for sigma ligands against
N-methyl-D-aspartate (NMDA), and hypoxiamediated neurotoxicity in neuronal culture toxicity studies. Brain. Res. 675, 110-120 (1995).
Lohi, J., Wilson, C.L., Roby, J.D., Parks, W.C. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and
keratinocytes and in response to injury. J. Biol. Chem. 276, 10134-10144 (2001).
Löscher, W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 16, 669–694 (2002).
Lu, Y., Wahl, L.M. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3
kinase/Akt/IKK{alpha}/NF-{kappa}B pathway. J. Leukoc. Biol.
[Epub ahead of print] (2005).
Mackman, N., Brand, K., Edgington, T.S. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J. Exp. Med. 174, 1517-1526 (1991).
Maldonado, J.R. Intravenous versus oral haloperidol: an evaluation of the incidence of extra-pyramidal symptoms. Psychosomatics 41, 169-170 (2000).
Marquez-Curtis, L.A., Dobrowsky, A., Montaño, J., Turner, A.R., Ratajczak, J., Ratajczak, M.Z., Janowska-Wieczorek, A. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br. J. Haematol.
115, 595–604 (2001).
Martin, R.D., Hoeth, M., Hofer-Warbinek, R., Schmid, J.A. The transcription factor NF-kB and the regulation of vascular cell function. Arterioscler. Thromb. Vasc. Biol. 20, e83- e88 (2000).
Masure, S., Nys, G., Fiten, P., Van Damme, J., Opdenaker, G. Mouse gelatinase B, cDNA cloning, regulation of expression and
glycosylation in WEHI-3 macrophages and gene organisation. Eur. J.
Biochem. 15, 129–141 (1993).
Mattson, M.P., Culmsee, C., Yu, Z., Camandola, S. Roles of nuclear factor kappa B in neuronal survival and plasticity. J. Neurochem. 74, 443-456 (2000).
May, M.J., Ghosh, S. IkappaB kinases: kinsmen with different crafts.
Science 284, 271-273 (1999).
Mayhan, W.G. Regulation of blood–brain barrier permeability.
Microcirculation 8, 89–104 (2001).
McCawley, L.J., Matrisian, L.M. Matrix metalloproteinases:
multifunctional contributors to tumor progression. Mol. Med. Today.
6, 149–156 (2000).
McCracken, G.H. Jr., Mustafa, M.M., Ramilo, O., Olsen, K.D., Risser, R.C. Cerebrospinal fluid interleukin 1 beta and tumor necrosis factor concentrations and outcome from neonatal Gram-negative enteric bacillary meningitis. Pediatr. Infect. Dis. J. 8, 155-159 (1989).
Mercurio, F., Zhu, H., Murray, B.W., Shevchenko, A., Bennett, B.L., Li, J., Young, D.B., Barbosa, M., Mann, M., Manning, A., Rao, A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for
NF-kappa B activation. Science 278, 860-866 (1997).
Mielke, K., Herdegen, T. JNK and p38 stresskinases-degenerative
effectors of signal-transduction-cascades in the nervous system. Prog.
Neurobiol. 61, 45-60 (2000).
Molica, S., Vitelli, G., Levato, D., Giannarelli, D., Vacca, A., Cuneo, A.
Increased serum levels of MMP-9 predict clinical outcome of patients with early B-CLL. Eur. J. Haematol. 70, 373–378 (2003).
Moon, S.K., Cha, B.Y., Kim, C.H. ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulaiton of NF-kappa B and AP-1: Involvement of the ras dependent pathway. J. Cell Physiol. 198, 417-427 (2004).
Moots, R.J., Al-Saffar, Z., Hutchinson, D., Golding, S.P., Young, S.P., Bacon, P.A., McLaughlin, P.J. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann. Rheum. Dis. 58, 585-587 (1999).
Morrison, D.C., Ryan, J.L. Endotoxins and disease mechanisms. Annu.
Rev. Med. 38, 417– 432 (1997).
Muller, J.M., Ziegler-Heitbrock, H.W., Baeuerle, P.A. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 187, 233-256 (1993).
Mun-Bryce, S., Rosenberg, G.A. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am. J.
Physiol. 274, R1203-R1211 (1998).
Munoz-Fernandez, M.A., Fresno, M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog.
Neurobiol. 56, 307–340 (1998).
Murthy, P.K., Dennis, V.A., Lasater, B.L., Philipp, M.T. Interleukin-10 modulates proinflammatory cytokines in the human monocytic cell line THP-1 stimulated with Borrelia burgdorferi lipoproteins. Infect.
Immun. 68, 6663–6669 (2000).
Nagatsu, T., Mogi, M., Ichinose, H., Togari, A. Cytokines in Parkinson’s disease.J. Neural. Transm. Suppl, 143-151 (2000).
Nakamura, Y. Regulating factors for microglial activation. Biol. Pharm.
Bull. 25, 945–953 (2002).
Nakano, H., Shindo, M., Sakon, S., Nishinaka, S., Mihara, M., Yagita, H., Okumura, K. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and
mitogen-activated protein kinase/ERK kinase kinase-1. Proc. Natl.
Acad. Sci. U.S.A. 95, 3537-3542 (1998).
Noh, J.S., Kang, H.J., Kim, E.Y., Sohn, S., Chung, Y.K., Kim, S.U., Gwag, B.J. Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase. J. Neurochem. 75, 2327-2334 (2000).
O’Neill, L.A. and Kaltschmidt, C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 20, 252-258 (1997).
O'Connell, M.A., Bennett, B.L., Mercurio, F., Manning, A.M., Mackman, N. Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J. Biol. Chem. 273, 30410-30414 (1998).
Özenci, V., Rinaldi, L., Teleshova, N., Matusevicius, D., Kivisäkk, P., Kouwenhoven, M., Link, H. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J. Autoimmun. 12, 297–303 (1999).
Pagenstecher, A., Stalder, A.K., Kincaid, C.L., Volk, B., Campbell, I.L.
Regulation of matrix metalloproteinases and their inhibitor genes in
Regulation of matrix metalloproteinases and their inhibitor genes in